{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:58:02Z","timestamp":1790794682743,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03551-y","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:29:21Z","timestamp":1790792961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intranasal Delivery of a Thermosensitive Gel Co-loaded with Temozolomide and N-acetylcysteine: In Vitro and In Vivo Evaluation"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3863-6349","authenticated-orcid":false,"given":"Raghda abd el moneum Ali Abdel","family":"Mawla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4880-8397","authenticated-orcid":false,"given":"Wedad","family":"Sakran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9920-0925","authenticated-orcid":false,"given":"Fares Ibrahim Farag","family":"Masry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3980-4036","authenticated-orcid":false,"given":"Mohammed Salah Ahmed","family":"Teiama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"3551_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.ijbiomac.2018.05.093","volume":"116","author":"A Khan","year":"2018","unstructured":"Khan A, Aqil M, Imam SS, Ahad A, Sultana Y, Ali A, et al. Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: Characterization, nasal absorption, histopathology and cell line study. Int J Biol Macromol. 2018;116:1260\u20137. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.05.093.","journal-title":"Int J Biol Macromol"},{"key":"3551_CR2","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.xphs.2020.04.004","volume":"109","author":"LH Salem","year":"2020","unstructured":"Salem LH, El-Feky GS, Fahmy RH, El Gazayerly ON, Abdelbary A. Coated lipidic nanoparticles as a new strategy for enhancing nose-to-brain delivery of a hydrophilic drug molecule. J Pharm Sci. 2020;109:2237\u201351. https:\/\/doi.org\/10.1016\/j.xphs.2020.04.004.","journal-title":"J Pharm Sci"},{"key":"3551_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/polym14122379","volume":"14","author":"R Fan","year":"2022","unstructured":"Fan R, Cheng Y, Wang R, Zhang T, Zhang H, Li J, et al. Thermosensitive hydrogels and advances in their application in disease therapy. Polymers (Basel). 2022;14:2379. https:\/\/doi.org\/10.3390\/polym14122379.","journal-title":"Polymers (Basel)"},{"key":"3551_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejpb.2019.01.018","volume":"136","author":"MJ Ramalho","year":"2019","unstructured":"Ramalho MJ, Andrade S, Coelho M\u00c1N, Loureiro JA, Pereira MC. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156\u201363. https:\/\/doi.org\/10.1016\/j.ejpb.2019.01.018.","journal-title":"Eur J Pharm Biopharm"},{"key":"3551_CR5","doi-asserted-by":"publisher","unstructured":"Oliver L, Lalier L, Salaud C, Heymann D, Cartron PF, Vallette FM. Drug resistance in glioblastoma: are persisters the key to therapy? Cancer Drug Resist. 2020;3:287. https:\/\/doi.org\/10.20517\/cdr.2020.03","DOI":"10.20517\/cdr.2020.03"},{"key":"3551_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1078155220912170","volume":"27","author":"K Lingertat-Walsh","year":"2021","unstructured":"Lingertat-Walsh K, Weilnau J, Cober MP, Ostrenga A, Poon B, Sales P, et al. Stability of extemporaneously compounded temozolomide 10 mg\/mL suspensions in Oral Mix SF\u00ae in glass and plastic bottles and plastic syringes. J Oncol Pharm Pract. 2021;27:78\u201387. https:\/\/doi.org\/10.1177\/1078155220912170.","journal-title":"J Oncol Pharm Pract"},{"key":"3551_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3174\/ajnr.A2170","volume":"31","author":"JR Wesolowski","year":"2010","unstructured":"Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (temodar). Am J Neuroradiol. 2010;31:1383\u20134. https:\/\/doi.org\/10.3174\/ajnr.A2170.","journal-title":"Am J Neuroradiol"},{"key":"3551_CR8","doi-asserted-by":"publisher","unstructured":"Muggeri A, Vago M, P\u00e9rez S, Rubio M, Gonz\u00e1lez C, Magarinos C, et al. A randomized, open-label, two-way crossover, single-dose bioequivalence study of temozolomide 200 mg\/m2 (Dralitem\u00ae vs. Temodal\u00ae capsules) in patients with primary tumors of the central nervous system under fasting conditions. Drugs R D. 2017;17:427\u201334. https:\/\/doi.org\/10.1007\/s40268-017-0196-1","DOI":"10.1007\/s40268-017-0196-1"},{"key":"3551_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00280-022-04423-7","volume":"89","author":"S B\u00fcsker","year":"2022","unstructured":"B\u00fcsker S, J\u00e4ger W, Poschner S, Mayr L, Al Jalali V, Gojo J, et al. Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors. Cancer Chemother Pharmacol. 2022;89:617\u201327. https:\/\/doi.org\/10.1007\/s00280-022-04423-7.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3551_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/C2015-0-01446-0","volume-title":"Handbook of brain tumor chemotherapy, molecular therapeutics, and immunotherapy","author":"HB Newton","year":"2018","unstructured":"Newton HB. Handbook of brain tumor chemotherapy, molecular therapeutics, and immunotherapy. Academic Press; 2018. https:\/\/doi.org\/10.1016\/C2015-0-01446-0."},{"key":"3551_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020217","volume":"15","author":"M Guerini","year":"2022","unstructured":"Guerini M, Condr\u00f2 G, Friuli V, Maggi L, Perugini P. N-Acetylcysteine (NAC) and its role in clinical practice management of cystic fibrosis (CF): a review. Pharmaceuticals (Basel). 2022;15:217. https:\/\/doi.org\/10.3390\/ph15020217.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3551_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2469486","volume":"2018","author":"SL Ooi","year":"2018","unstructured":"Ooi SL, Green R, Pak SC. N\u2010acetylcysteine for the treatment of psychiatric disorders: a review of current evidence. Biomed Res Int. 2018;2018:2469486. https:\/\/doi.org\/10.1155\/2018\/2469486.","journal-title":"Biomed Res Int"},{"key":"3551_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2165\/00003088-199120020-00004","volume":"20","author":"MR Holdiness","year":"1991","unstructured":"Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20:123\u201334. https:\/\/doi.org\/10.2165\/00003088-199120020-00004.","journal-title":"Clin Pharmacokinet"},{"key":"3551_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/bdd.2510110205","volume":"11","author":"L Borgstr\u00f6m","year":"1990","unstructured":"Borgstr\u00f6m L, K\u00e5gedal B. Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Biopharm Drug Dispos. 1990;11:131\u20136. https:\/\/doi.org\/10.1002\/bdd.2510110205.","journal-title":"Biopharm Drug Dispos"},{"key":"3551_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF01061422","volume":"34","author":"B Olsson","year":"1988","unstructured":"Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol. 1988;34:77\u201382. https:\/\/doi.org\/10.1007\/BF01061422.","journal-title":"Eur J Clin Pharmacol"},{"key":"3551_CR16","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1016\/0006-2952(89)90677-1","volume":"38","author":"K Sj\u00f6din","year":"1989","unstructured":"Sj\u00f6din K, Nilsson E, Hallberg A, Tunek A. Metabolism of N-acetyl-l-cysteine some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol. 1989;38:3981\u20135. https:\/\/doi.org\/10.1016\/0006-2952(89)90677-1.","journal-title":"Biochem Pharmacol"},{"key":"3551_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1378\/chest.107.5.1437","volume":"107","author":"N van Zandwijk","year":"1995","unstructured":"van Zandwijk N. N-acetylcysteine for lung cancer prevention. Chest. 1995;107:1437\u201341. https:\/\/doi.org\/10.1378\/chest.107.5.1437.","journal-title":"Chest"},{"key":"3551_CR18","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1161\/01.cir.92.10.2855","volume":"92","author":"MA Arstall","year":"1995","unstructured":"Arstall MA, Yang J, Stafford I, Betts WH, Horowitz JD. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction: safety and biochemical effects. Circulation. 1995;92:2855\u201362. https:\/\/doi.org\/10.1161\/01.cir.92.10.2855.","journal-title":"Circulation"},{"key":"3551_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00401-010-0798-y","volume":"121","author":"M Garrido","year":"2011","unstructured":"Garrido M, Tereshchenko Y, Zhevtsova Z, Taschenberger G, B\u00e4hr M, K\u00fcgler S. Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons. Acta Neuropathol. 2011;121:475\u201385. https:\/\/doi.org\/10.1007\/s00401-010-0798-y.","journal-title":"Acta Neuropathol"},{"key":"3551_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jconrel.2015.12.015","volume":"240","author":"H Cho","year":"2016","unstructured":"Cho H, Gao J, Kwon GS. PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol\u2013gels for drug delivery. J Control Release. 2016;240:191\u2013201. https:\/\/doi.org\/10.1016\/j.jconrel.2015.12.015.","journal-title":"J Control Release"},{"key":"3551_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9070600","volume":"9","author":"L Mursaleen","year":"2020","unstructured":"Mursaleen L, Noble B, Chan SHY, Somavarapu S, Zariwala MG. N-Acetylcysteine nanocarriers protect against oxidative stress in a cellular model of Parkinson\u2019s disease. Antioxidants (Basel). 2020;9:600. https:\/\/doi.org\/10.3390\/antiox9070600.","journal-title":"Antioxidants (Basel)"},{"key":"3551_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1208\/s12249-020-01851-x","volume":"21","author":"M Nasr","year":"2020","unstructured":"Nasr M, Hashem F, Abdelmoniem R, Tantawy N, Teiama M. In vitro cytotoxicity and cellular uptake of tamoxifen citrate-loaded polymeric micelles. AAPS PharmSciTech. 2020;21:306. https:\/\/doi.org\/10.1208\/s12249-020-01851-x.","journal-title":"AAPS PharmSciTech"},{"key":"3551_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jbm.820060609","volume":"6","author":"IR Schmolka","year":"1972","unstructured":"Schmolka IR. Artificial skin I. Preparation and properties of pluronic F\u2010127 gels for treatment of burns. J Biomed Mater Res. 1972;6:571\u201382. https:\/\/doi.org\/10.1002\/jbm.820060609.","journal-title":"J Biomed Mater Res"},{"key":"3551_CR24","unstructured":"Mahadlek J. Development of thermosensitive gel of doxycycline hyclate containing zinc oxide. \u0e21\u0e2b\u0e32\u0e27\u0e34\u0e17\u0e22\u0e32\u0e25\u0e31\u0e22 \u0e28\u0e34\u0e25\u0e1b\u0e32\u0e01\u0e23; 2008."},{"key":"3551_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.21608\/ajps.2014.6953","volume":"50","author":"G Abdel Bary","year":"2014","unstructured":"Abdel Bary G. Preparation and characterization of thermosensitive mucoadhesive in_situ gels for nasal delivery of ondansetron hydrochloride. Al-Azhar J Pharm Sci. 2014;50:191\u2013207.","journal-title":"Al-Azhar J Pharm Sci"},{"key":"3551_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijpharm.2011.02.019","volume":"409","author":"T Ur-Rehman","year":"2011","unstructured":"Ur-Rehman T, Tavelin S, Gr\u00f6bner G. Chitosan in situ gelation for improved drug loading and retention in poloxamer 407 gels. Int J Pharm. 2011;409:19\u201329. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.02.019.","journal-title":"Int J Pharm"},{"key":"3551_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/10611860903386928","volume":"18","author":"S Khan","year":"2010","unstructured":"Khan S, Patil K, Bobade N, Yeole P, Gaikwad R. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target. 2010;18:223\u201334. https:\/\/doi.org\/10.3109\/10611860903386928.","journal-title":"J Drug Target"},{"key":"3551_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1208\/s12249-013-9925-y","volume":"14","author":"RMP Singh","year":"2013","unstructured":"Singh RMP, Kumar A, Pathak K. Thermally triggered mucoadhesive in situ gel of loratadine: \u03b2-cyclodextrin complex for nasal delivery. AAPS PharmSciTech. 2013;14:412\u201324. https:\/\/doi.org\/10.1208\/s12249-013-9925-y.","journal-title":"AAPS PharmSciTech"},{"key":"3551_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1023\/a:1015812615635","volume":"7","author":"EE Hassan","year":"1990","unstructured":"Hassan EE, Gallo JM. A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Pharm Res. 1990;7:491\u20135. https:\/\/doi.org\/10.1023\/a:1015812615635.","journal-title":"Pharm Res"},{"key":"3551_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejps.2012.10.024","volume":"48","author":"S Pund","year":"2013","unstructured":"Pund S, Rasve G, Borade G. Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. Eur J Pharm Sci. 2013;48:195\u2013201. https:\/\/doi.org\/10.1016\/j.ejps.2012.10.024.","journal-title":"Eur J Pharm Sci"},{"key":"3551_CR31","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1080\/03639045.2017.1361966","volume":"43","author":"R Zainuddin","year":"2017","unstructured":"Zainuddin R, Zaheer Z, Sangshetti JN, Momin M. Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation. Drug Dev Ind Pharm. 2017;43:2076\u201384. https:\/\/doi.org\/10.1080\/03639045.2017.1361966.","journal-title":"Drug Dev Ind Pharm"},{"key":"3551_CR32","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1016\/j.actbio.2011.07.025","volume":"7","author":"U Seju","year":"2011","unstructured":"Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 2011;7:4169\u201376. https:\/\/doi.org\/10.1016\/j.actbio.2011.07.025.","journal-title":"Acta Biomater"},{"key":"3551_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00459","volume":"10","author":"M Kazi","year":"2019","unstructured":"Kazi M, Al-Swairi M, Ahmad A, Raish M, Alanazi FK, Badran MM, et al. Evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for poorly water-soluble talinolol: preparation, in vitro and in vivo assessment. Front Pharmacol. 2019;10:459. https:\/\/doi.org\/10.3389\/fphar.2019.00459.","journal-title":"Front Pharmacol"},{"key":"3551_CR34","unstructured":"Guideline IHT. Stability testing of new drug substances and products. Q1A (R2), Curr step. 2003;4."},{"key":"3551_CR35","doi-asserted-by":"publisher","unstructured":"Farid RM, Etman MA, Nada AH, Ebian A-EA. Sodium alginate-based microspheres of salbutamol sulphate for nasal administration: Formulation and evaluation. Am J Pharma Tech Res. 2012;2:289\u2013307. https:\/\/doi.org\/10.3389\/fphar.2022.965789","DOI":"10.3389\/fphar.2022.965789"},{"key":"3551_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.965789","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang S, Yu Y, Wang A, Duan X, Sun Y, Wang L, et al. Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration. Front Pharmacol. 2022;13:965789. https:\/\/doi.org\/10.3389\/fphar.2022.965789.","journal-title":"Front Pharmacol"},{"key":"3551_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4103\/jpbs.jpbs_548_22","volume":"15","author":"R Shamsheer","year":"2023","unstructured":"Shamsheer R, Sunoqrot S, Kasabri V, Shalabi D, Alkhateeb R, Alhiari Y, et al. Preparation and Characterization of Capsaicin Encapsulated Polymeric Micelles and Studies of Synergism with Nicotinic Acids as Potential Anticancer Nanomedicines. J Pharm Bioallied Sci. 2023;15:107\u201325. https:\/\/doi.org\/10.4103\/jpbs.jpbs_548_22.","journal-title":"J Pharm Bioallied Sci"},{"key":"3551_CR38","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.apsb.2014.10.005","volume":"4","author":"M Yasir","year":"2014","unstructured":"Yasir M, Sara UVS. Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. Acta Pharm Sin B. 2014;4:454\u201363. https:\/\/doi.org\/10.1016\/j.apsb.2014.10.005.","journal-title":"Acta Pharm Sin B"},{"key":"3551_CR39","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ijpharm.2014.07.025","volume":"473","author":"YM Gabal","year":"2014","unstructured":"Gabal YM, Kamel AO, Sammour OA, Elshafeey AH. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int J Pharm. 2014;473:442\u201357. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.07.025.","journal-title":"Int J Pharm"},{"key":"3551_CR40","doi-asserted-by":"publisher","unstructured":"Peer CJ, Ronner L, Rodgers L, Lester McCully CM, Warren KE, Figg WD. Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. Separations. 2016;3. https:\/\/doi.org\/10.3390\/separations3030023","DOI":"10.3390\/separations3030023"},{"key":"3551_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0021-9673(99)00995-0","volume":"870","author":"C Celma","year":"2000","unstructured":"Celma C, Allu\u00e9 JA, Pru\u00f1onosa J, Peraire C, Obach R. Determination of N-acetylcysteine in human plasma by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr A. 2000;870:13\u201322. https:\/\/doi.org\/10.1016\/s0021-9673(99)00995-0.","journal-title":"J Chromatogr A"},{"key":"3551_CR42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3109\/21691401.2015.1012260","volume":"44","author":"P Kaur","year":"2016","unstructured":"Kaur P, Garg T, Rath G, Goyal AK. In situ nasal gel drug delivery: a novel approach for brain targeting through the mucosal membrane. Artif Cells Nanomed Biotechnol. 2016;44:1167\u201376. https:\/\/doi.org\/10.3109\/21691401.2015.1012260.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"3551_CR43","first-page":"250","volume":"3","author":"PS Khairnar","year":"2011","unstructured":"Khairnar PS, Walke PS, Narkhede MR, Nehete JY. Formulation and in-vitro evaluation of thermoreversible rizatriptan benzoate nasal gel. Int J Pharm Pharm Sci. 2011;3:250\u20136.","journal-title":"Int J Pharm Pharm Sci"},{"key":"3551_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ijpharm.2018.07.014","volume":"548","author":"NAH Abou Youssef","year":"2018","unstructured":"Abou Youssef NAH, Kassem AA, Farid RM, Ismail FA, El-Massik MAE, Boraie NA. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: preparation, characterization and in vivo evaluation. Int J Pharm. 2018;548:609\u201324. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.07.014.","journal-title":"Int J Pharm"},{"key":"3551_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijpharm.2009.01.002","volume":"372","author":"DS Jones","year":"2009","unstructured":"Jones DS, Bruschi ML, de Freitas O, Gremi\u00e3o MPD, Lara EHG, Andrews GP. Rheological, mechanical and mucoadhesive properties of thermoresponsive, bioadhesive binary mixtures composed of poloxamer 407 and carbopol 974P designed as platforms for implantable drug delivery systems for use in the oral cavity. Int J Pharm. 2009;372:49\u201358. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.01.002.","journal-title":"Int J Pharm"},{"key":"3551_CR46","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","volume":"134","author":"S Grassin-Delyle","year":"2012","unstructured":"Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc L-J, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012;134:366\u201379. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.03.003.","journal-title":"Pharmacol Ther"},{"key":"3551_CR47","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s11095-006-9103-0","volume":"23","author":"G Dumortier","year":"2006","unstructured":"Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23:2709\u201328. https:\/\/doi.org\/10.1007\/s11095-006-9103-0.","journal-title":"Pharm Res"},{"key":"3551_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2005.01.007","volume":"60","author":"D Dodou","year":"2005","unstructured":"Dodou D, Breedveld P, Wieringa PA. Mucoadhesives in the gastrointestinal tract: revisiting the literature for novel applications. Eur J Pharm Biopharm. 2005;60:1\u201316. https:\/\/doi.org\/10.1016\/j.ejpb.2005.01.007.","journal-title":"Eur J Pharm Biopharm"},{"key":"3551_CR49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/03639040802360528","volume":"35","author":"IA Alsarra","year":"2009","unstructured":"Alsarra IA, Hamed AY, Mahrous GM, El Maghraby GM, Al-Robayan AA, Alanazi FK. Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir. Drug Dev Ind Pharm. 2009;35:352\u201362. https:\/\/doi.org\/10.1080\/03639040802360528.","journal-title":"Drug Dev Ind Pharm"},{"key":"3551_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1246974","volume":"11","author":"R Cai","year":"2023","unstructured":"Cai R, Zhang L, Chi H. Recent development of polymer nanomicelles in the treatment of eye diseases. Front Bioeng Biotechnol. 2023;11:1246974. https:\/\/doi.org\/10.3389\/fbioe.2023.1246974.","journal-title":"Front Bioeng Biotechnol"},{"key":"3551_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ejpb.2018.04.016","volume":"128","author":"V Bourganis","year":"2018","unstructured":"Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharm Verfahrenstechnik eV. 2018;128:337\u201362. https:\/\/doi.org\/10.1016\/j.ejpb.2018.04.016.","journal-title":"Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharm Verfahrenstechnik eV"},{"key":"3551_CR52","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jconrel.2017.10.030","volume":"268","author":"G Zhai","year":"2017","unstructured":"Zhai G, Khan M, Liu M, Khan A. Progress in brain targeting drug delivery system by nasal route. J Control Release. 2017;268:364\u201389. https:\/\/doi.org\/10.1016\/j.jconrel.2017.10.030.","journal-title":"J Control Release"},{"key":"3551_CR53","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jddst.2019.03.008","volume":"51","author":"D Gadhave","year":"2019","unstructured":"Gadhave D, Gorain B, Tagalpallewar A, Kokare C. Intranasal teriflunomide microemulsion: An improved chemotherapeutic approach in glioblastoma. J Drug Deliv Sci Technol [Internet]. 2019;51:276\u201389. https:\/\/doi.org\/10.1016\/j.jddst.2019.03.008.","journal-title":"J Drug Deliv Sci Technol [Internet]"},{"key":"3551_CR54","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.2147\/DDDT.S230919","volume":"13","author":"MM Omar","year":"2019","unstructured":"Omar MM, Eleraky NE, El Sisi AM, Ali HO. Development and Evaluation of in-situ Nasal Gel Formulations of Nanosized Transferosomal Sumatriptan: Design, Optimization, in vitro and in vivo Evaluation. Drug Des Devel Ther. 2019;13:4413\u201330. https:\/\/doi.org\/10.2147\/DDDT.S230919.","journal-title":"Drug Des Devel Ther"},{"key":"3551_CR55","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","volume":"57","author":"MI Ugwoke","year":"2005","unstructured":"Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57:1640\u201365. https:\/\/doi.org\/10.1016\/j.addr.2005.07.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"3551_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118807","volume":"572","author":"V Gervasi","year":"2019","unstructured":"Gervasi V, Cullen S, McCoy T, Crean A, Vucen S. Application of a mixture DOE for the prediction of formulation critical temperatures during lyophilisation process optimisation. Int J Pharm. 2019;572:118807. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118807.","journal-title":"Int J Pharm"},{"key":"3551_CR57","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.2147\/IJN.S418049","volume":"18","author":"UA Fahmy","year":"2023","unstructured":"Fahmy UA, Ahmed OAA, Badr-Eldin SM, Aldawsari HM, Okbazghi SZ, Awan ZA, et al. Optimized Nanostructured Lipid Carriers Integrated into in situ Nasal Gel for Enhancing Brain Delivery of Flibanserin [Retraction]. Int J Nanomedicine. 2023;18:2253\u20134. https:\/\/doi.org\/10.2147\/IJN.S418049.","journal-title":"Int J Nanomedicine"},{"key":"3551_CR58","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrd4333","volume":"13","author":"VP Torchilin","year":"2014","unstructured":"Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13:813\u201327. https:\/\/doi.org\/10.1038\/nrd4333.","journal-title":"Nat Rev Drug Discov"},{"key":"3551_CR59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Pra\u00e7a C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.044.","journal-title":"J Control Release"},{"key":"3551_CR60","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941\u201351. https:\/\/doi.org\/10.1038\/nbt.3330.","journal-title":"Nat Biotechnol"},{"key":"3551_CR61","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.addr.2012.10.003","volume":"65","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev. 2013;65:104\u201320. https:\/\/doi.org\/10.1016\/j.addr.2012.10.003.","journal-title":"Adv Drug Deliv Rev"},{"key":"3551_CR62","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ejps.2012.12.007","volume":"48","author":"S Md","year":"2013","unstructured":"Md S, Khan RA, Mustafa G, Chuttani K, Baboota S, Sahni JK, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2013;48:393\u2013405. https:\/\/doi.org\/10.1016\/j.ejps.2012.12.007.","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci"},{"key":"3551_CR63","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3109\/10717544.2013.868557","volume":"22","author":"BM Shah","year":"2015","unstructured":"Shah BM, Misra M, Shishoo CJ, Padh H. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug Deliv. 2015;22:918\u201330. https:\/\/doi.org\/10.3109\/10717544.2013.868557.","journal-title":"Drug Deliv"},{"key":"3551_CR64","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/10611861003734001","volume":"19","author":"S Patel","year":"2011","unstructured":"Patel S, Chavhan S, Soni H, Babbar AK, Mathur R, Mishra AK, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target. 2011;19:468\u201374. https:\/\/doi.org\/10.3109\/10611861003734001.","journal-title":"J Drug Target"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03551-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:29:23Z","timestamp":1790792963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03551-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":64,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3551"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03551-y","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol of the study was approved by the Animal Ethics Committee of Faculty of Pharmacy, Helwan University, No. 24 A2024.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have given their consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript is not under consideration for publication elsewhere.","order":3,"name":"Ethics","label":"Submission declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cThe authors have no relevant financial or non-financial interests to disclose.\u201d","order":4,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare to have NO conflict of interest in this article.","order":5,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analyzed during the current study are original without any fabrication, falsification or bias towards particular outcomes.","order":6,"name":"Ethics","label":"Data Fabrication or Falsification","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that no generative artificial intelligence (AI) tools were used in the preparation of the data, figures, or text of this manuscript. All content was generated and verified by the authors.","order":7,"name":"Ethics","label":"Declaration of generative AI use","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"318"}}